1. Unmet Needs in the Secondary Prevention in ACS

3. GRACE 5-Year Mortality

4. Antiplatelet Therapy Cornerstone of Medical Therapy Post ACS

5. TRA 2P-TIMI 50 Efficacy/Safety

9. ATLAS ACS 2—TIMI 51 Study Design

10. ATLAS-2 Baseline Patient Characteristics

11. ATLAS-2 Baseline Medications

14. ATLAS-2 Efficacy of Rivaroxaban 2.5 mg BID

15. ATLAS-2 Safety End Points

16. APPRAISE-2 Apixaban Plus Antiplatelet Therapy Post ACS

17. Patients at High Risk for Recurrent Ischemic Events

18. Antithrombotic Options for Secondary Prevention of Ischemic Events

20. ATLAS-2 Summary

21. Abbreviations

22. Abbreviations (cont)

23. Abbreviations (cont)

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)